ARTICLE | Clinical News
RBX7455: Ph I started
January 5, 2017 9:59 PM UTC
Rebiotix began an open-label, U.S. Phase I trial to evaluate twice-daily oral RBX7455 for 2 or 4 days in about 20 patients....
BCIQ Company Profiles
Rebiotix began an open-label, U.S. Phase I trial to evaluate twice-daily oral RBX7455 for 2 or 4 days in about 20 patients....
BCIQ Company Profiles